Processing .....please wait.. 
The article has been forwarded.... 
News >> Technology >>
Inder Verma on NuGEN's scientific advisory board
By siliconindia
|
Friday, 13 December 2002, 20:30 IST |
3 Comments
SAN CARLOS: NuGEN Technologies, Inc., Friday announced the appointment of Inder M. Verma to its scientific advisory board.
Dr. Verma brings over 30 years of scientific research and development experience in the fields of molecular medicine, gene therapy, oncology and immunotherapy. He is currently an American Cancer Society professor of Molecular Biology in the Laboratory of Genetics at the Salk Institute, as well an adjunct professor in the Department of Biology at University of California, San Diego. Dr. Verma is member of the National Academy of Sciences, U.S.A. & Institute of Medicine.
"We are delighted to welcome Dr. Verma to our Scientific Advisory Board," said Jan D'Alvise, President and CEO of NuGEN Technologies. "His scientific expertise and industry experience will be extremely helpful as we rapidly progress towards the commercialization of our gene expression products, and begin the development of new applications for our analysis and detection technologies."
NuGEN's amplification technologies can be used to successfully amplify nanogram amounts of DNA and RNA. The technologies will enable scientists to significantly expand the scope of their research by enabling them to perform studies on very minute amounts of precious samples that previously could not be readily analyzed. The sensitivity, simplicity and accuracy of these products makes them well suited for use with a wide range of existing platforms including microarrays, biochips, beads, microfluidics and other miniaturized devices used in thousands of laboratories worldwide.
"I am pleased to serve on NuGEN's scientific advisory board," Dr. Verma said. "The SPIA(TM) and Ribo-SPIA(TM) nucleic acid amplification technologies have the potential to fundamentally change how we conduct gene expression profiling and differential expression analysis."
NuGEN plans to launch its first commercial gene expression product in early 2003 and is currently seeking early technology access partners and research collaborations within the biotechnology and pharmaceutical industry. The Company is also exploring licensing opportunities for its technologies for military/biological warfare, agbiotech, veterinary and food processing applications.
Dr. Verma received a master's degree in biochemistry from Lucknow University in India and a Ph.D. from the Weizmann Institute of Science in Israel. After postdoctoral study at the Massachusetts Institute of Technology, he joined the Salk Institute. He is a member of the National Academy of Sciences, American Academy of Arts and Sciences, the Institute of Medicine, and the Third World Academy of Sciences, and a March of Dimes Birth Defects Foundation Franklin D. Roosevelt Investigator. He is the past President of the American Society of Gene Therapy and recipient of an NIH Outstanding Investigator award.